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Abstract
Obesity and type 2 diabetes are occurring at epidemic rates in the United States and many parts of
the world. The "obesity epidemic" appears to have emerged largely from changes in our diet and
reduced physical activity. An important but not well-appreciated dietary change has been the
substantial increase in the amount of dietary fructose consumption from high intake of sucrose and
high fructose corn syrup, a common sweetener used in the food industry. A high flux of fructose
to the liver, the main organ capable of metabolizing this simple carbohydrate, perturbs glucose
metabolism and glucose uptake pathways, and leads to a significantly enhanced rate of de novo
lipogenesis and triglyceride (TG) synthesis, driven by the high flux of glycerol and acyl portions of
TG molecules from fructose catabolism. These metabolic disturbances appear to underlie the
induction of insulin resistance commonly observed with high fructose feeding in both humans and
animal models. Fructose-induced insulin resistant states are commonly characterized by a profound
metabolic dyslipidemia, which appears to result from hepatic and intestinal overproduction of
atherogenic lipoprotein particles. Thus, emerging evidence from recent epidemiological and
biochemical studies clearly suggests that the high dietary intake of fructose has rapidly become an
important causative factor in the development of the metabolic syndrome. There is an urgent need
for increased public awareness of the risks associated with high fructose consumption and greater
efforts should be made to curb the supplementation of packaged foods with high fructose additives.
The present review will discuss the trends in fructose consumption, the metabolic consequences
of increased fructose intake, and the molecular mechanisms leading to fructose-induced
lipogenesis, insulin resistance and metabolic dyslipidemia.
Emerging epidemic of the Metabolic Syndrome
The new millennium has witnessed the emergence of a
modern epidemic, the metabolic syndrome, with frightful
consequences to the health of humans worldwide. The
metabolic syndrome, also referred to as "Diabesity" [1]
describes the increasing incidence of diabetes in combina-
tion with obesity as a result of changes in human behav-
iour, available nutrition, and the adoption of more
sedentary lifestyles. Obesity and type 2 diabetes are occur-
ring at epidemic rates in the United States [2-4] and devel-
oping countries including China [5] and India [6]. From
1935 to 1996, the prevalence of diagnosed type 2 diabetes
climbed nearly 765% [7]. The global figures are predicted
to rise 46% from 150 million cases in 2000 to 221 million
in 2010 [8]. This epidemic of type 2 diabetes is compli-
cated by the fact that it is a multi-factorial disease, fre-
quently associated with a cluster of pathologies including
obesity, hypertriglyceridemia, impaired glucose tolerance,
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and insulin resistance, collectively referred to as the meta-
bolic syndrome (formerly known as syndrome X and
insulin resistance syndrome). Although there is no univer-
sally accepted definition of the metabolic syndrome, most
would agree that the syndrome includes a cluster of com-
mon pathologies: obesity, insulin resistance, dyslipi-
demia, and hypertension. It is present in 25–50% of the
United States population [9]. There has been a heightened
awareness of the metabolic syndrome and a subsequent
increase in clinical attention directed towards prevention,
due to its strong association with premature morbidity
and mortality [8,10]. In particular, these risk factors pre-
dispose the individual to greater risk for developing cardi-
ovascular disease and Type 2 diabetes. Recently, the
National Cholesterol Education Panel (NCEP) has offi-
cially described and identified a number of these risk fac-
tors for cardiovascular diseases [11]. These include: 1)
abdominal obesity, 2) elevated TG levels, 3) low high
density lipoprotein (HDL)-cholesterol levels, 4) increased
blood pressure, and 5) impaired fasting glucose [12].
There is also now consensus that insulin resistance and
obesity are actually part of one common pathologic
mechanism of the metabolic syndrome [13,14]. Evidence
shows that the metabolic syndrome process begins early
in life and persistence from childhood to adolescent/adult
life produces type 2 diabetes and cardiovascular disease
[15,16]. The symptoms of metabolic syndrome are not
necessarily manifestations of age, but develop over a pre-
disposed background established at a young age [17,18].
This is a dangerous predisposition, with trends in modern
diet and habit likely influencing health and behaviour in
increasingly younger populations.
The main driving forces for the increased prevalence of
insulin resistance are modern Westernized diets and pat-
terns of eating associated with the dramatic rises in obes-
ity. Insulin resistance is often linked to the macronutrient
content in the diet. In the past, diets high in saturated fats
have been shown to induce weight gain, insulin resist-
ance, and hyperlipidemia in humans and animals [19-
22]. Recent research suggests that a high intake of refined
carbohydrates may also increase the risk of insulin resist-
ance [23-26]. In addition, diets specifically high in fruc-
tose have been shown to contribute to a metabolic
disturbance in animal models resulting in weight gain,
hyperlipidemia [27], and hypertension [28].
Nutritional factors influencing the development 
of the Metabolic Syndrome
Nutrition represents a lifestyle element that can be con-
trolled, and that can directly influence health; therefore
preventative nutrition and weight control should become
a main focus of consumers and prepared-food providers
[29]. The Westernization of diets, with an increase in
availability of high calorie foods certainly contributes to
the epidemic of metabolic syndrome. In the past, physi-
cians and scientists have made an association between
dietary energy from fat and body fat. A large market has
developed for the popularity and promotion of low fat
diets. Interestingly, however, the decline in dietary fat
consumption has not corresponded to a decrease in obes-
ity – in fact, the opposite trend has emerged [30]. Cer-
tainly, diets high in saturated fats have been shown to
induce weight gain, insulin resistance, and hyperlipi-
demia in humans and animals [19-22,31], but the
emphasis on fat reductions has had no significant benefits
relative to the obesity epidemic. More importantly, the
focus on dietary fat is more likely a distraction to more sig-
nificant causes of metabolic syndrome [30]. If fat is not
the culprit in metabolic disorders, then what is? Increas-
ing evidence now suggests that the rise in consumption of
carbohydrates, particularly refined sugars high in fructose,
appears to be at least one very important contributing
factor.
Carbohydrates and the link to the Metabolic 
Syndrome
The general increases in consumption of calories, and spe-
cifically of refined carbohydrates and fructose, is clear and
correlates positively with an alarming increases in meta-
bolic syndrome. Can these seemingly harmless nutrients
actually be directly associated with metabolic syndrome?
Recent studies appear to support this link. In a 2004
study, Gross et al examined nutrient consumption in the
United States between 1909 and 1997, and discovered
there was a significant correlation in the prevalence of dia-
betes with fat, carbohydrate, corn syrup, and total energy
intakes. Most striking was the fact that when total energy
intake was accounted for, corn syrup was positively asso-
ciated with type 2 diabetes, while protein and fat were not
[32]. High fructose corn syrups (HFCS) are quite com-
monly found in soft drinks and juice beverages, and are
incorporated into many convenient pre-packaged foods,
such as breakfast cereals and baked goods. Fructose con-
sumption has thus largely increased over the past few dec-
ades most likely as a result of this increased use of HFCS,
which contains between 55–90% fructose. The use of
HFCS has increased an alarming 1000% between 1970
and 1990 [33]. In 1970, individual consumption of fruc-
tose was only 0.5 lb/year. However, in 1997, this figure
rose to an alarming 62.4 lb/year [34]. The type of com-
mon, general use sweeteners represent as large an impact
as the dramatic increase in the use of these caloric sweeten-
ers. Between 1909 and 1997, sweetener use increased by
86%; and specifically, corn syrup sweeteners now repre-
sent over 20% of total daily carbohydrate intake, at an
increase of 2100% [32].
These documented trends have inspired a number of con-
sumption studies and recommendations towards HFCSNutrition & Metabolism 2005, 2:5 http://www.nutritionandmetabolism.com/content/2/1/5
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intake. In 1992, the USDA recommended that only 40 g
of extra sugars should be added to a standard 2000 calorie
a day diet [35]. The amount of HFCS found in only one
12-oz soft drink equals this total proportion of daily
intake. HFCS consumption trends are further exacerbated
by the fact that soft drink and fruit juice consumption
itself has increased dramatically, adding even more extra-
neous calories and fructose to the diet. From 1965 to
1996, a food consumption study involving 11 to 18 year
olds revealed that total energy and fat intakes were
decreasing. There were significant decreases in milk con-
sumption but large increases in the consumption of soft
drinks and non-citrus juices [36]. Increasingly, children
seem to be choosing mass-produced, 'tasty' artificial juices
and sodas over healthier alternatives. In a recent letter to
the editor, Jacobson [37] illustrates some important fac-
tors that contribute to increased consumption of soft
drinks, and the link to obesity; a) Society is constantly
bombarded by huge million-dollar advertising campaigns
for soft drinks, offered extra-extra-large serving sizes with
free refills, and surrounded by ubiquitous access to soft
drink vending machines even in schools, and b) children's
standard drinks to accompany meals, and especially fast
food, have become soft drinks. The increased use of HFCS
in soft drinks and food products are thus exacerbated by
increased exposure, and consumption of these products.
HFCS are the main caloric sweeteners utilized in soft
drinks in the United States, with fructose representing
over 40% of sweeteners added to prepared foods and bev-
erages [33]. In a study of females aged 12 to 19 years milk
intake decreased by 36%, whereas sodas and fruit drink
consumption increased to nearly double from the 1970s
to the mid 1990s. From 1994 to 1996, it was found that
even though intake of soda, juices, tea, and alcoholic bev-
erages remained constant, the steady decrease of milk
intake continued [38]. This becomes a major problem,
because while these high-calorie beverages are being con-
sumed, calories from the rest of the diet are not subse-
quently reduced. The reality is that people do not
eliminate or reduce their food portions because they
drank a can of soda that day. Data indicate that energy
from beverages generally does not displace or decrease
energy from other foods consumed, leading to energy
imbalances [39]. The main diet issues involve a general
lack of education and/or understanding of the implica-
tions with recent consumption patterns. Despite educa-
tion programs to prevent obesity and diabetes worldwide,
there has been little focus on the reduction of fructose and
HFCS in beverages.
Fructose metabolism
Fructose is readily absorbed and rapidly metabolized by
human liver. For thousands of years humans consumed
fructose amounting to 16–20 grams per day, largely from
fresh fruits. Westernization of diets has resulted in signifi-
cant increases in added fructose, leading to typical daily
consumptions amounting to 85–100 grams of fructose
per day. The exposure of the liver to such large quantities
of fructose leads to rapid stimulation of lipogenesis and
TG accumulation, which in turn contributes to reduced
insulin sensitivity and hepatic insulin resistance/glucose
intolerance. These negative effects of fructose are the rea-
son that fructose metabolism has gained recent research
attention. Interestingly, small catalytic quantities of fruc-
tose can have positive effects, and actually decrease the
glycemic response to glucose loads, and improve glucose
tolerance. These effects are also observed without any
changes in insulin responses and non-esterified fatty acid
(NEFA) and TG levels [40,41]. In 1976, sugar substitutes
such as fructose had been found to offer the 'advantage' of
a 'better' utilization in conditions of limited insulin pro-
duction. Fructose had a smaller influence on serum insu-
lin concentrations than glucose, and no influence on
plasma glucose levels. At that time, this evidence was con-
sidered to support fructose as a positive treatment for dia-
betic control [40]. In 1986 HFCS were even proposed as a
low-cost substitute for fructose in diabetic management.
Based on these early observations, nutritive sweeteners
were considered safe by the Food and Drug Administra-
tion, although, it has now been found that intakes above
25% of total energy consumed will cause hypertriglyceri-
demia and gastrointestinal symptoms [42]. Even with the
early positive results, researchers noticed accompanying
"unfavorable" influences of these so-called diabetic sugars
on obesity and weight gain. Certain metabolic differences
exist between glucose and fructose, and the results that
were once thought favorable, proved exacerbating to insu-
lin resistance and obesity. In a study comparing normal
and diabetic patients, glycemic effects of HFCS were com-
pared to glucose. The negative results of HFCS on immu-
noreactive insulin, glycemic effect, and immunoreactive
C-peptide did not support its use as a substitute for glu-
cose in diabetic patients [43].
Unfortunately, one out of every four children in the
United States consumes above the recommended 25% of
total energy intake from sweeteners [42] and the harmful
effects of fructose have been extensively studied in
healthy, non-diabetic patients. Studies involving com-
monly consumed fruit juices showed that natural fructose
carbohydrates can alter lipid and protein oxidation
biomarkers in the blood, and mediate oxidative stress
responses in vivo [44]. A comparative study by Raben et al.
examined overweight men and women who consumed
fructose-containing sucrose, as opposed to artificial sweet-
eners as supplements to their diet. Weight, fat mass, and
blood pressure were found to be lower in the artificial
sweetener-consuming group compared to the sucrose-
consuming group, and the sucrose group did not decrease
intake of other nutrients to compensate for their increasedNutrition & Metabolism 2005, 2:5 http://www.nutritionandmetabolism.com/content/2/1/5
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calorie consumption from the sucrose. Subjects consum-
ing the sweetener did not exhibit increases in energy
intake, weight, and blood pressure that seen in the
sucrose-consuming subjects [45]. Research in the metabo-
lism of fructose has left more questions about the differ-
ence between short-term positive effects, and the negative
effects of chronic, long-term use of fructose sugars [46].
The long-term negative effects can include changes in
digestion, absorption, plasma hormone levels, appetite,
and hepatic metabolism, leading to development of insu-
lin resistance, diabetes, obesity, and inevitably cardiovas-
cular disease.
When the metabolic pathways and characteristics of fruc-
tose are examined more closely, many of the questions
about its positive and negative effects can be answered.
Fructose is a potent regulator of glycogen synthesis and
liver glucose uptake. Therefore any catalytic improve-
ments are due to hepatic glucokinase and glucose uptake
facilitation. However, as mentioned, the beneficial effects
do not continue with chronic fructose utilization [47].
Because of its lipogenic properties, excess fructose in the
diet can cause glucose and fructose malabsorption, and
greater elevations in TG and cholesterol compared to
other carbohydrates [48]. There are key differences in the
metabolic pathways that glucose and fructose follow.
Upon gastric absorption both fructose and glucose are
delivered via the portal vein to the liver. It is believed that
the ability of the liver to metabolize high doses of fructose
is responsible for the disruption in energy stores and fuel
metabolism observed [49-52]. In the liver, fructose is
metabolized into glyceraldehyde and dihydroxyacetone
phosphate. These particular fructose end products can
then readily converge with the glycolytic pathway. Of key
importance is the ability of fructose to by-pass the main
regulatory step of glycolysis, the conversion of glucose-6-
phosphate to fructose 1,6-bisphosphate, controlled by
phosphofructokinase. Thus, while glucose metabolism is
negatively regulated by phosphofructokinase, fructose can
continuously enter the glycolytic pathway. Therefore, fruc-
tose can uncontrollably produce glucose, glycogen, lac-
tate, and pyruvate, providing both the glycerol and acyl
portions of acyl-glycerol molecules. These particular sub-
strates, and the resultant excess energy flux due to unregu-
lated fructose metabolism, will promote the over-
production of TG (reviewed in [53]).
The glycemic index (GI) has been commonly used to dif-
ferentiate and compare various nutrients, as well as to
describe how different foods produce different plasma
glucose levels after ingestion. The GI can range from 100
for glucose and baked potato compared to approximately
20 for fructose and whole barley [54]. Foods with varying
GIs have different time courses associated with satiety.
High GI carbohydrates have been reported to reduce
appetite in the short term, whereas low GI carbohydrates
possess a more delayed effect on energy intake controls
[55]. Fructose appears to have differing effects on appetite
compared to glucose, contributing to its negative proper-
ties. Anderson et al. determined the association between
food intake and blood glucose, comparing glucose and a
fructose mixture. Glucose was administered as a high GI
preload, which resulted in lower mealtime energy intakes
compared to the low GI preload of the glucose-fructose
mixture. An inverse relationship was seen between GI
(and blood glucose concentrations), and appetite with
consequent increased food intakes seen with fructose
[56]. In 2002, Vozzo et al. studied the comparative effects
of glucose and fructose on blood glucose, insulin, and
acute food intake. When subjects drank equienergetic
preloads of glucose or fructose before an ad libidum buffet
lunch, glucose concentrations were lower in the fructose
group compared to glucose, and insulin concentrations
were 50% higher in the fructose group in type 2 diabetics
than in non-diabetics. The authors concluded that fruc-
tose may be a suitable replacement for glucose in diabetic
patients – although it was found that satiating efficiencies
of fructose certainly offered no advantages [57]. This study
differs from others with regards to insulin secretion, but
the trend is clear between GI, glucose concentrations, and
appetite. An explanation for the variation in glucose and
fructose glycemic responses appears to be dependent on
rates of hydrolysis and absorption of glucose, and gastric
emptying [58]. The variations observed in GI and appetite
control of glucose and fructose can also be explained by
differences in stimulation of insulin and leptin, important
players in the long-term regulation of energy homeostasis.
Fructose will generally produce smaller insulin excursions
upon consumption because it does not stimulate the
secretion of insulin from pancreatic beta cells, whereas
glucose does. Insulin-regulated leptin will also have a
reduced concentration and a decreased net effect on
reducing appetite. Limited effects on appetite suppres-
sion, combined with the fact that fructose is favoured by
the liver to be metabolized into lipid, will subsequently
lead to weight gain, hyperinsulinemia, and the associated
insulin resistance [59]. Glucose and fructose comparison
studies continued examining new hormonal targets. In
2004, Teff et al. showed that subjects served meals with
either 30% glucose beverages, or 30% fructose beverages,
had differing hormonal and metabolic responses. Glyc-
emic  excursions  and insulin responses were reduced by
66% and 65%, respectively, in the fructose-consuming
subjects. There was a concomitant reduction in circulating
leptin both in the short and long-term as well as a 30%
reduction in ghrelin (an orexigenic gastroenteric hor-
mone) in the fructose group compared to the glucose
group. A prolonged elevation of TG was also seen in the
high fructose subjects [60]. Both fat and fructose con-
sumption usually results in low leptin concentrationsNutrition & Metabolism 2005, 2:5 http://www.nutritionandmetabolism.com/content/2/1/5
Page 5 of 14
(page number not for citation purposes)
which, in turn, leads to overeating in populations con-
suming energy from these particular macronutrients. An
adipocyte hormone, adiponectin, also plays an important
role in lipid homeostasis and insulin action [61]. The
insulin sensitizer agonist, peroxisome proliferator-acti-
vated receptor-gamma, stimulates adiponectin produc-
tion and adiponectin is in fact thought to be part of this
agonist's mechanism lowering circulating fatty acids and
increasing fat oxidation. The net effect is to decrease liver
TG and increase insulin sensitivity [62]. Chronic fructose
consumption reduces adiponectin responses, contribut-
ing to insulin resistance [63].
Animal studies have illustrated various differences
between glucose and fructose metabolism. In 2002, Miller
et al. injected fructose into the cerebroventricles of rats,
and observed enhanced food intake, whereas similar con-
centrations of injected glucose suppressed appetite-ago-
nist stimulated food intake [64]. Feeding rats either 32%
glucose, fructose, or sucrose solutions, resulted in
increased weight gain, and energy consumption com-
pared to chow fed controls. Rats given the fructose and
sucrose solutions also had a decreased ability to tolerate a
glucose load, and fructose animals had greater serum TG
levels over all other conditions ([65]. This is likely because
the hepatic metabolism of fructose favours de novo lipo-
genesis. In combination with alterations in insulin signal-
ing and leptin regulation, weight gain and unregulated
energy intake can occur [33]. In 1986, Levine et al. found
that fructose, administered in the form of the disaccharide
sucrose, promotes obesity more than glucose because
fructose does not stimulate thermogenesis [58]. These
hormonal and physiological changes illustrate the impor-
tant connections between energy intake, appetite control,
weight gain, and insulin resistance.
Fructose and insulin resistance
Increasingly, questions have been raised as to whether
dietary carbohydrate and fructose intake are directly
related to the development of type 2 diabetes. As insulin
resistance is often associated with circulating C-peptide
concentrations, a cross-sectional study was performed to
assess dietary fructose and carbohydrate, and glycemic
loads related to C-peptide concentrations. It was found
that the highest quintile of fructose intake had 13.9%
higher C-peptide concentrations than the lowest quintile.
Of note, subjects with high intakes of cereal fiber had
15.6% lower C-peptide concentrations, indicating that
these types of nutrients may have opposing roles in the
development of insulin resistance [66]. A definite rela-
tionship has also been found between metabolic syn-
drome and hyperhomocysteinemia, which is associated
with cardiovascular and cerebrovascular diseases. Rats fed
a fructose-enriched diet had a 72% higher homocysteine
levels after 5 weeks compared to chow-fed controls [67].
Elevated homocysteine levels are an important risk factor
for vascular disease. Homocysteine was found to be
higher in patients with stenotic vessels and coronary
artery disease scores, and was in fact highest in diabetic
patients [68]. This is consistent with the increased TG,
very low density lipoprotein (VLDL) secretion, and
atherosclerosis associated with chronic fructose feeding.
Although fructose does not appear to acutely increase
insulin levels, chronic exposure seems to indirectly cause
hyperinsulinemia and obesity through other mecha-
nisms. One proposed mechanism involves GLUT5, a fruc-
tose transporter that is found to have significantly higher
expression levels in young Zucker obese rats compared to
lean controls. As the rats age and become diabetic, GLUT5
abundance and activity is compromised, causing an even
more marked insulin resistance over lean rats, implying a
possible role of GLUT5 receptors in the pathology of met-
abolic syndrome associated with fructose feeding and
insulin resistance [69]. In rats fed 66% fructose for 2
weeks, insulin receptor mRNA, and subsequent insulin
receptor numbers in skeletal muscle and liver were signif-
icantly lower compared to rats fed a standard chow diet.
Also, blood pressure and plasma TG increased in the fruc-
tose-fed rats, even though there was no change in plasma
insulin, glucose, or body weight [70]. Evidence shows
these early steps in insulin signaling are important for
insulin's metabolic effects. In a different study, it was
found that after 28 days of fructose feeding there were no
changes in insulin receptor concentration, but, insulin
stimulated autophosphorylation, a mechanism necessary
for insulin action, was reduced to 72% in the liver. Insulin
receptor substrate (IRS) protein levels were similar, but
there were significant decreases in insulin induced IRS (1/
2) phosphorylation in both the liver and muscle of the
fructose fed rats [71]. These changes are important,
because it has been shown that the products of these insu-
lin independent metabolic pathways lead to polyol for-
mation and advanced glycation end products, which can
contribute to the numerous complications and premature
atherosclerosis seen in diabetic patients [58]. It is also
known that such inflammations can lead to the pathogen-
esis of diabetes, and there is strong evidence suggesting
that increased free fatty acids (FFA) in diabetic subjects
and fructose fed models play a role in the inflammatory
state of insulin resistance. If FFA are not removed from tis-
sues, as occurs in fructose fed insulin resistant models,
there is an increased energy and FFA flux that leads to the
increased secretion of TG. Insulin resistance has also been
correlated with intracellular TG stores, which are involved
in lipotoxicity and beta cell failure leading to diabetes
[72]. Another theory explaining how chronic fructose
overnutrition can lead to type 2 diabetes is the hex-
osamine hypothesis, where hexosamine flux is thought to
regulate glucose and satiety-sensing pathways. WithNutrition & Metabolism 2005, 2:5 http://www.nutritionandmetabolism.com/content/2/1/5
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overexpression of glutamine:fructose-6-phosphate ami-
dotransferase, the key regulatory enzyme in hexosamine
synthesis, the liver produces excess fatty acids, skeletal
muscle becomes insulin resistant, and hyperinsulinemia
results. This pathway of excess hexosamine flux leads to
long-term storage of energy, and eventually obesity and
type 2 diabetes [73].
Fructose: a highly lipogenic nutrient
There is considerable evidence supporting the ability of
high fructose diets to upregulate the lipogenesis pathway,
leading to increased TG production [74]. Insulin and glu-
cose are known to directly regulate lipid synthesis and
secretion. Insulin controls hepatic sterol regulatory ele-
ment binding protein (SREBP) expression, which is a key
transcription factor responsible for regulating fatty acid
and cholesterol biosynthesis. SREBP binds to sterol
responsive elements (SRE) found on multiple genes, and
can activate a cascade of enzymes involved in cholesterol
biosynthetic pathways, such as HMG-CoA reductase [75]
and fatty acid synthase (FAS) [76]. Miyazaki et al. reported
an induction of the hepatic SREBP-1 isoform and lipo-
genic gene expression including FAS, acetyl-CoA carboxy-
lase (ACC), and stearoyl-CoA desaturase (SCD) in mice
following 7 days on a 60% fructose diet [77]. It is known
that SREBPs are regulated by intracellular sterol concen-
trations. However, more recently, it has been established
that hormones such as insulin and platelet derived growth
factor play a role in regulating these transcription factors.
Expression of SREBP is enhanced by insulin in all three
major insulin target tissues, liver, fat, and skeletal muscle
[78-81]. Similarly, levels of SREBP are enhanced in the
presence of hyperinsulinemia [82,83]. There is evidence
that the insulin-mediated stimulation of SREBP occurs
through the MAP kinase pathway [84], with ERK1/2 being
shown to activate the SREBP-1a isoform by phosphorylat-
ing serine 117) [85]. Despite the fact that SREBP-1 is
directly stimulated via insulin signaling, the depletion of
insulin and insulin signaling through streptozotocin
(STZ) treatment paradoxically induces SREBP-1c expres-
sion upon glucose, fructose, or sucrose feeding. It would
have been expected that SREBP-1c would be downregu-
lated concomitantly along with the reduced insulin avail-
ability, but this is not the case. Glucose feeding causes a
short-term peak induction, whereas fructose caused a
gradual extended increase in SREBP-1c activity, providing
evidence that lipogenesis can be independent of insulin
signaling, given carbohydrate, and particularly fructose,
availability [86].
Emerging evidence suggests that a protein phosphatase,
known as PTP-1B, may link high carbohydrate feeding,
insulin resistance, and lipogenesis. Recently, PTP-1B has
been linked to lipogenesis and SREBP regulation. Shimizu
et al. found that overexpression of protein tyrosine phos-
phatase 1B (PTP-1B), which is associated with dysfunc-
tional insulin signaling, leads to increased mRNA and
promoter activity of SREBP-1c, and subsequent increases
in the expression of FAS. PTP-1B may therefore regulate
the lipogenesis and hypertriglyceridemia associated with
insulin resistance syndrome [87]. In insulin resistant fruc-
tose fed rats, it has been reported that the increase of
hepatic SREBP-1 mRNA [88] occurs in correlation with an
increased PTP-1B expression [87]. The authors established
a role for PTP-1B in enhancing SREBP-1 gene expression
through upregulation of Sp1 transcriptional activity, via
an increase in protein phosphatase 2A activity [87]. FAS,
an important downstream component of lipid synthesis,
was extensively studied in rat livers. Dietary carbohydrates
increased the transcriptional rate of FAS in comparison to
proteins. Specifically, fructose feeding increased FAS
mRNA concentrations, and somewhat increased tran-
scriptional rate. This suggests that fructose may increase
the stability of FAS mRNA, while carbohydrates stimulate
FAS through increased transcriptional rate [89]. Other
studies using animal models of insulin resistance, for
example, the Wistar fatty rats, showed the effects of dietary
carbohydrates on TG production. Feeding rats fructose
stimulated FAS, and created a 56% increase in TG secre-
tion rate, and an 86% increase in plasma TG. Feeding glu-
cose, however, did not have this effect on TG production,
nor did it affect induction of FAS. This is likely because
glucose stimulates both TG production, and TG removal,
maintaining homeostasis. Fructose stimulates TG produc-
tion, but impairs removal, creating the known dyslipi-
demic profile [90]. The human liver possesses a large
capacity to metabolize fructose to lipids because of its
ability to shunt metabolism toward serum TG production.
TG stores supply an energy 'sink', providing an almost
unlimited TG production capacity. Conversely, glucose as
opposed to fructose would decrease serum TG [91]. As
discussed earlier, the effects of fructose in promoting TG
synthesis are independent of insulinemia. Hirsch argued
that carbohydrate overload results in elevated TG because
the large amounts of sugar that need to be absorbed so
rapidly from the intestine lead to the involvement of other
metabolic pathways, such as the hexose monophosphate
shunt, that that favour the synthesis of FFA [92]. Again,
the liver takes up dietary fructose rapidly where it can be
converted to glycerol-3-phosphate. This substrate favours
esterification of unbound FFA to form the TG [93]. It has
also been found that increases of 1,2-sn-diacylglycerol
and elevated expression of a PKC isoenzyme are associ-
ated with the enhanced synthesis of TG observed with
high fructose diet models [94]. In these scenarios, where
there is excess hepatic fatty acid uptake, synthesis and
secretion, 'input' of fats in the liver exceed 'outputs', and
hepatic steatosis occurs [95]. The mechanisms of steatosis
and liver enlargement due to fructose intake are not well
understood, but it is believed to be related to microsomalNutrition & Metabolism 2005, 2:5 http://www.nutritionandmetabolism.com/content/2/1/5
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enzyme induction, increased storage of lipids, peroxisome
proliferation, and hyperfunction due to excessive hepatic
'workloads' [96]. All of these factors contribute to fructose
being a highly lipogenic nutrient, and to the resultant
hepatic steatosis.
Mechanisms of fructose induced lipoprotein 
overproduction
There is growing evidence that the insulin resistant state
developed upon fructose feeding is also associated with
stimulated hepatic VLDL secretion. Several animal models
have been employed to examine the mechanisms of this
induction of VLDL, and the subsequent increases in
plasma TG observed. Mechanistic studies based on carbo-
hydrate versus lipid metabolism have recently become
important because carbohydrate induced hypertriglyceri-
demia shares a metabolic basis with high fat diet induced
endogenous hypertriglycerolemia. The similarly induced
dyslipidemias would therefore have the same or similar
atherogenic risks [97]. Carbohydrate induced hypertrig-
lycerolemia results from a combination of both TG over-
production, and inadequate TG clearance [97,98]. These
disease processes and the hepatic steatosis caused by stim-
ulated lipogenesis have been illustrated by fructose fed
animal models showing how aberrant leptin signaling,
hyperinsulinemia, and dyslipidemia are related to TG
induction [95]. Animals maintained on a chronic high
fructose diet develop elevated NEFA and hyperinsuline-
mia at the expense of glycemic control [99]. This is not
surprising, as fructose-induced metabolic dyslipidemia is
usually accompanied by whole body insulin resistance
[100] and reduced hepatic insulin sensitivity [101]. In the
fructose fed hamster model, animals showed decreased
glucose disappearance rates, increased plasma NEFA and
increased plasma and liver TG [27]. Figure 1 (adapted
from ref. 100) shows clear in vivo evidence of fructose-
induced insulin resistance as assessed by euglycemic
hyperinsulinemic clamp studies. Taghibiglou et al. further
characterized the fructose fed hamster model demonstrat-
ing the development of a metabolic dyslipidemic state
characterized by high plasma levels of VLDL-TG and apol-
ipoprotein B (apoB) due to hepatic lipoprotein overpro-
duction [100]. Serum TGs are elevated via  both an
increased secretion, and decreased clearance of VLDL
[102]. Also, high rates of lipolysis in visceral adipose
depots can increase availability of NEFAs and promote
hepatic TG synthesis. The TG is then packaged with apoB,
and secreted as VLDL particles [93]. Evidence has shown
that there is a complex interplay of cellular enzymes regu-
lating lipid synthesis and uptake, as well as export and
oxidation. Observations of the actions of insulin affecting
lipid secretion as well as inhibition of TG has brought
research interests towards the effects of chronic insulin
stimulation on VLDL secretion and transport. Excess
VLDL secretion has been shown to deliver increased fatty
acids and TG to muscle and other tissues, further inducing
insulin resistance [103]. Induced cellular changes include
alterations in hepatic pyruvate dehydrogenase, changes in
insulin signaling phosphorylation, and increases of
inflammatory cytokines [104,105]. It is evident that the
metabolic effects of fructose occur through rapid utiliza-
tion in the liver due to the bypassing of the regulatory
phosphofructokinase step in glycolysis. This in turn
causes activation of pyruvate dehydrogenase, and subse-
quent modifications favoring esterification of fatty acids,
again leading to increased VLDL secretion [53]. Increases
in VLDL secretion can then lead to chain reactions in
other lipoproteins and lipids, such as low density lipopro-
tein (LDL). Resultant LDL cholesterol levels induced by
high fructose intake are illustrated by comparison of a diet
including 20% fructose, contrasted to a starch diet of less
than 3% fructose. The 20% fructose diet initiated a cycle
of increased fasting serum total and LDL cholesterol of 9%
and 11%, respectively, over the starch feeding [106].
Increased evidence was shown in transgenic apo AI-CIII-
AIV mice, fed a fructose solution for 9 months, where dif-
ferential expressions of the apo AI and apo AIV genes were
found. This indicated general perturbations in response to
dietary intakes, causing long-term adverse effects in this
hyperlipidemia mouse model [107]. The male Wistar fatty
rat model of obese type 2 diabetes has also shown hyper-
glycemia. Remarkably, the female Wistar rats only
develop this hyperglycemia when given sucrose, contain-
ing the responsible element of fructose, which causes
increases in gluconeogenic enzymes and decreases in glu-
cokinase. A hypertriglyceridemic effect is seen, presuma-
bly due to hepatic overproductions of VLDL and
induction of lipogenic enzymes via dietary fructose [108].
Another contributing factor to VLDL overproduction
includes fructose effects on lipid peroxidation. High fruc-
tose diets can have a hypertriglyceridemic and pro-oxi-
dant effect, and fructose fed rats have shown less
protection from lipid peroxidation. Replacing the fructose
in these diets with a more natural source of high fructose,
honey, reduces this susceptibility and lowers plasma
nitrite and nitrate levels [109]. In 2004, Kelley et al.
hypothesized that pro-oxidant stress response pathways
may mediate hepatic increases in VLDL secretion and
delayed clearance upon fructose feeding. Hypertriglyceri-
demic fructose fed rats were treated with lipoxygenase
inhibitors, which reversed the inflammatory protein activ-
ity response, and the lipid dysregulation observed [102].
Recent findings have also shown that the hyperlipidemic
and pro-oxidant effect induced by a high fructose diet can
be decreased by oligofructose consumption. Oligofruc-
tose administered to fructose fed rats did not alter insulin
concentrations, and lowered plasma leptin by 50% com-
pared to control groups. Oligofructose prevented TG
changes induced by fructose feeding, and decreasedNutrition & Metabolism 2005, 2:5 http://www.nutritionandmetabolism.com/content/2/1/5
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hepatic TG accumulation. The peroxidation effect of fruc-
tose was also decreased by oligofructose, and had benefi-
cial protective effects [110]. Oxidative stress has often
been implicated in the pathology of insulin resistance
induced by fructose feeding, and lipid peroxides, diene
conjugates, and reactive substances are undeniably ele-
vated in fructose fed animals, especially accompanying a
deficient antioxidant system. Administration of alpha-
Fructose-induced insulin resistance: evidence from euglycemic hyperinsulinemic clamp studies Figure 1
Fructose-induced insulin resistance: evidence from euglycemic hyperinsulinemic clamp studies. Mean glucose 
levels (A) were slightly but significantly higher in fructose-fed vs. control animals during the last 30 mins of the clamp period (p 
< 0.01). Mean insulin levels (B) were slightly but not significantly higher in the fructose-fed vs. control hamsters during the 
clamp period. The glucose infusion rate (Ginf) (C) during the clamp period was significantly lower in fructose-fed vs. control 
animals (p < 0.01). The calculated insulin sensitivity index (SI – see methods) (D) was also significantly lower in the fructose-fed 
vs. control hamsters (p = 0.03). Fructose-fed (n = 9), control hamsters (n = 10). (adapted from Taghibiglou et al. [100]).
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lipoic acid (LA) has been shown to prevent these changes,
and improve insulin sensitivity [111]. LA treatment also
prevents several deleterious effects of fructose feeding: the
increases in cholesterol, TG, activity of lipogenic enzymes,
and VLDL secretion, the reductions in lipoprotein lipase
and HDL cholesterol and may even normalize a dyslipi-
demic cholesterol distribution of plasma lipoproteins
[112]. Taken together, this evidence shows a clear role of
peroxidative stress pathways involved in VLDL
oversecretion.
Observations made in our own laboratory have also
shown aberrant lipogenesis activity. In primary hepato-
cytes isolated from fructose fed hamsters, there were sig-
nificant increases in LXRα, SREBP-1, FAS and SCD, which
indicate increased activity of the lipogenic pathways
(unpublished observations). Fructose has also been
implicated in reducing PPARα levels in rat hepatocytes.
PPARα is a ligand activated nuclear hormone receptor that
is responsible for inducing mitochondrial and peroxiso-
mal β-oxidation. Nagai et al. found that following 8 weeks
of a high fructose diet, rats showed decreased PPARα
mRNA and protein levels [88]. In addition, primary rat
hepatocytes treated with fructose also showed decreased
PPARα expression, suggesting that fructose or its metabo-
lites can directly regulate lipid oxidation. We have also
recently detected decreased mRNA levels of PPARα in
both liver and intestine of the fructose fed hamster
(unpublished observations). Hence, decreased PPARα
expression can result in reduced oxidation, leading to cel-
lular lipid accumulation. For example, PPARα null mice
have extensive hepatic steatosis because of diminished β-
oxidation capacity, such as seen in the insulin resistant
state [113]. Other mechanisms have been illustrated by
Taghibiglou et al., who found evidence for enhanced lipo-
protein assembly, reduced intracellular apoB degradation,
and increased microsomal triglyceride transfer protein
(MTP) mass, mRNA and activity in the fructose fed ham-
ster [100]. These metabolic changes also coincided with a
decrease in ER-60, a cysteine protease that may play a role
in apoB degradation, and an increase in synthesis and
secretion of apoB [101]. It appears that a complex rela-
tionship exists in the fructose fed animal model that links
insulin resistance and dyslipidemia through NEFA flux,
SREBP-1 expression, de novo lipogenesis and MTP expres-
sion. Amplified MTP activity and expression would be
expected to stimulate the assembly and secretion of apoB-
lipoproteins, as an association has been demonstrated
between MTP levels and VLDL production [114]. As insu-
lin is a negative regulator of MTP gene expression [115],
the upregulation of MTP that has been observed in insulin
resistance states is predictable. MTP is also negatively reg-
ulated by SREBP through sterol response element (SRE)
regions located within -124 and -116 of the 5' MTP gene
promoter [116]. However, in fructose fed animals [87] as
well as other models of insulin resistance [117] where
increased levels of MTP and SREBP have been established,
the regulatory effects of SREBP may play a minor role in
regulating MTP expression. Rather increased hepatic
NEFA and increased TG stores might stimulate MTP
expression [118]. Recent observations in our laboratory
show that oleic acid can stimulate the MTP promoter and
the stimulation occurs independently of SRE activity
(unpublished observations). Thus, in insulin resistance
states, increased MTP may occur through another mecha-
nism that may block SREBP-mediated inhibition of the
promoter. These phenomena help explain the increased
assembly and secretion of apoB in fructose fed models. In
addition, increased levels of small dense LDL particles
have been observed in insulin resistant states [119]. Early
studies by Verschoor et al. showed that fructose diets
altered the structure and function of VLDL particles caus-
ing and increase in the TG: protein ratio, and an increased
total cholesterol and phospholipid content [120]. LDL
particle size has been found to be inversely related to TG
concentration [121] and therefore the higher TG results in
a smaller, denser, more atherogenic LDL particle, which
contributes to the morbidity of the metabolic disorders
associated with insulin resistance. Several theories are pro-
posed for the overproduction of VLDL: more TG per VLDL
particle, increases in particle number, changes in the pro-
duction rates of VLDL TG or apoB, decreased TG clear-
ance, increased lipoprotein lipase activity, and increased
de novo lipogenesis. It is likely a combination of some or
all of these factors that contribute to the elevated TG seen
in a fructose rich carbohydrate fed model of metabolic
disorder. High fructose, which stimulates VLDL secretion,
may initiate the cycle that results in metabolic syndrome
long before type 2 diabetes and obesity develop [103].
More recently, our studies have identified an interesting
link between the development of insulin resistance and
deregulation of intestinal lipoprotein metabolism [122].
Chronic fructose feeding stimulated intestinal secretion of
apolipoprotein B48-containing lipoprotein particles
accompanied by enhanced intestinal lipid synthesis in the
form of free cholesterol, cholesterol ester, and triglyceride,
as well as increases in both MTP mass and activity. These
results suggest that in insulin resistant or diabetic animals,
there may be a mechanism causing enhanced intestinal
secretion of lipoproteins in the fasting state. Fructose feed-
ing may enhance this basal level of lipoprotein secretion
through increased de novo lipogenesis and increased MTP
availability. Comparison of plasma lipoproteins from
fructose-fed animals showed a significant shift toward
secretion of larger, less dense, chylomicrons in the insulin
resistant animals [123].Nutrition & Metabolism 2005, 2:5 http://www.nutritionandmetabolism.com/content/2/1/5
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Hepatic fructose metabolism: A highly lipogenic pathway Figure 2
Hepatic fructose metabolism: A highly lipogenic pathway. Fructose is readily absorbed from the diet and rapidly 
metabolized principally in the liver. Fructose can provide carbon atoms for both the glycerol and the acyl portions of triglycer-
ide. Fructose is thus a highly efficient inducer of de novo lipogenesis. High concentrations of fructose can serve as a relatively 
unregulated source of acetyl CoA. In contrast to glucose, dietary fructose does NOT stimulate insulin or leptin (which are 
both important regulators of energy intake and body adiposity). Stimulated triglyceride synthesis is likely to lead to hepatic 
accumulation of triglyceride, which has been shown to reduce hepatic insulin sensitivity, as well as increased formation of VLDL 
particles due to higher substrate availability, increased apoB stability, and higher MTP, the critical factor in VLDL assembly.
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Concluding remarks
The alarming increase in fructose consumption may be an
important contributor to the epidemic of obesity and
insulin resistant diabetes in both pediatric and adult
populations. For thousands of years, the human diet con-
tained a relatively small amount of naturally occurring
fructose from fruits and other complex foods. Adaptation
of humans to a high glucose/low fructose diet has meant
that hepatic carbohydrate metabolism is designed to
actively metabolize glucose with a limited capacity for
metabolizing a small daily intake of fructose. The increas-
ing application of high fructose sweeteners over the past
few decades has resulted in a considerable rise in the die-
tary intake of fructose. A high flux of fructose to the liver,
the main organ capable of metabolizing this simple car-
bohydrate, disturbs normal hepatic carbohydrate metabo-
lism leading to two major consequences (Figure 2):
perturbations in glucose metabolism and glucose uptake
pathways, and a significantly enhanced rate of de novo
lipogenesis and TG synthesis, driven by the high flux of
glycerol and acyl portions of TG molecules coming from
fructose catabolism. These metabolic disturbances appear
to underlie the induction of insulin resistance commonly
observed with high fructose feeding in both humans and
animal models. Fructose induced insulin resistant states
are commonly characterized by a profound metabolic
dyslipidemia, which appears to result from hepatic and
intestinal overproduction of atherogenic lipoprotein par-
ticles. Taking into consideration that a typical western diet
not only contains high levels of fructose but is also rich in
both fat and cholesterol, synergistic interactions among
these nutrients can readily occur leading to a greater
degree of insulin resistance and dyslipidemia. In conclu-
sion, emerging evidence from recent epidemiological and
biochemical studies clearly suggests that the high dietary
intake of fructose has rapidly become an important caus-
ative factor in the development of the metabolic syn-
drome. There is an urgent need for increased public
awareness of the risks associated with high fructose con-
sumption and greater efforts should be made to curb the
supplementation of packaged foods with high fructose
additives.
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